Posted by Michael Wonder on 12 May 2017
Proteon Therapeutics receives FDA breakthrough therapy designation for vonapanitase
10 May 2017 - Proteon Therapeutics today announced that its investigational treatment, vonapanitase, has received breakthrough therapy designation from the U.S. FDA for increasing arteriovenous fistula secondary patency (i.e., survival of the fistula without abandonment) and use for haemodialysis in patients on or expected to initiate haemodialysis.
